Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more product
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's weight loss drugs, growth outlook, and more.
▶︎
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
▶︎
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing
▶︎
Why Trump’s Iran deal is WORSE than Obama’s deal
▶︎
GLP-1 Weight Loss | 10 Things I Wish I Knew Before Starting
▶︎
The rally we've seen this year has been entirely driven by earnings, says JPMorgan's Stephen Parker
▶︎
The Next Phase Of The Obesity Drug Race
▶︎
J&J CEO Joaquin Duato on 2024 guidance, product pipeline and long-term growth outlook
▶︎
Exclusive: How Eli Lilly’s making weight loss drugs more accessible
▶︎
Eli Lilly CEO: How GLP-1s Will Reshape America
▶︎
Dr. Terry Dubrow on Ozempic, Peptides & Non-Surgical Anti-Aging for Longevity
▶︎
S13 E16: Iran Peace Deal & Feral Hogs: 6/21/26: Last Week Tonight with John Oliver
▶︎
AI Bubble Will Burst Eventually Says Bridgewater's Ray Dalio
▶︎
'We laid a very good foundation': Vance details progress in US-Iran talks
▶︎
How Treating Sleep Apnea Reduces Heart Attack Risk, Accelerates Weight Loss & Protects Your Brain
▶︎
Ozempic vs Zepound vs Retatrutide | Which is Best for Weight Loss?
▶︎
What Sam Altman Doesn't Want You To Know
▶︎
SpaceX IPO 'Will Be Volatile' Says Ark Invest's Cathie Wood
▶︎
Why Novo Nordisk’s Drugs Are Anti-Obesity Game-Changers: CNBC Healthy Returns Summit 2023
▶︎
The Dark Side Of Ozempic Nobody Talks About
▶︎